Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.

Peterson LF, Sun H, Liu Y, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun D, Jakubowiak A, Malek SN, Talpaz M, Donato NJ.

Blood. 2015 Jun 4;125(23):3588-97. doi: 10.1182/blood-2014-10-605584. Epub 2015 Mar 26.

2.

DUB-ling down on B-cell malignancies.

Boise LH.

Blood. 2015 Jun 4;125(23):3522-3. doi: 10.1182/blood-2015-04-638262.

3.

USP9X inhibition promotes radiation-induced apoptosis in non-small cell lung cancer cells expressing mid-to-high MCL1.

Kushwaha D, O'Leary C, Cron KR, Deraska P, Zhu K, D'Andrea AD, Kozono D.

Cancer Biol Ther. 2015;16(3):392-401. doi: 10.1080/15384047.2014.1002358.

4.

Deubiquitylating enzyme USP9x regulates radiosensitivity in glioblastoma cells by Mcl-1-dependent and -independent mechanisms.

Wolfsperger F, Hogh-Binder SA, Schittenhelm J, Psaras T, Ritter V, Bornes L, Huber SM, Jendrossek V, Rudner J.

Cell Death Dis. 2016 Jan 14;7:e2039. doi: 10.1038/cddis.2015.405.

5.

Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.

Karpel-Massler G, Banu MA, Shu C, Halatsch ME, Westhoff MA, Bruce JN, Canoll P, Siegelin MD.

Oncotarget. 2016 Mar 15;7(11):12791-805. doi: 10.18632/oncotarget.7302.

6.

Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells.

Yan J, Zhong N, Liu G, Chen K, Liu X, Su L, Singhal S.

Cell Death Dis. 2014 Jul 3;5:e1316. doi: 10.1038/cddis.2014.281.

7.

Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.

Venkata JK, An N, Stuart R, Costa LJ, Cai H, Coker W, Song JH, Gibbs K, Matson T, Garrett-Mayer E, Wan Z, Ogretmen B, Smith C, Kang Y.

Blood. 2014 Sep 18;124(12):1915-25.

8.

Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis.

Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ.

Cancer Res. 2010 Nov 15;70(22):9265-76. doi: 10.1158/0008-5472.CAN-10-1530. Epub 2010 Nov 2.

9.

Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival.

Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, Yue P, Dornan D, Huang DC, Dixit VM.

Nature. 2010 Jan 7;463(7277):103-7. doi: 10.1038/nature08646. Epub 2009 Dec 20.

PMID:
20023629
10.

Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1.

Trivigno D, Essmann F, Huber SM, Rudner J.

Neoplasia. 2012 Oct;14(10):893-904.

11.

Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance.

Zhou M, Wang T, Lai H, Zhao X, Yu Q, Zhou J, Yang Y.

Biochem Biophys Res Commun. 2015 Apr 3;459(2):333-339. doi: 10.1016/j.bbrc.2015.02.115. Epub 2015 Feb 28.

PMID:
25735983
12.

The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition.

Peddaboina C, Jupiter D, Fletcher S, Yap JL, Rai A, Tobin RP, Jiang W, Rascoe P, Rogers MK, Smythe WR, Cao X.

BMC Cancer. 2012 Nov 21;12:541. doi: 10.1186/1471-2407-12-541.

13.

Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.

Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G, Talpaz M, Donato NJ.

Blood. 2011 Mar 17;117(11):3151-62. doi: 10.1182/blood-2010-03-276477. Epub 2011 Jan 19.

14.

Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.

Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opferman JT, Sattler M, Anderson KC, J├Ąger D, Podar K.

Cancer Lett. 2014 Feb 28;343(2):286-94. doi: 10.1016/j.canlet.2013.09.042. Epub 2013 Oct 8.

PMID:
24120758
15.

Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response.

Perry JW, Ahmed M, Chang KO, Donato NJ, Showalter HD, Wobus CE.

PLoS Pathog. 2012;8(7):e1002783. doi: 10.1371/journal.ppat.1002783. Epub 2012 Jul 5.

16.

Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I).

Peng Z, Maxwell DS, Sun D, Bhanu Prasad BA, Schuber PT Jr, Pal A, Ying Y, Han D, Gao L, Wang S, Levitzki A, Kapuria V, Talpaz M, Young M, Showalter HD, Donato NJ, Bornmann WG.

Bioorg Med Chem. 2014 Feb 15;22(4):1450-8. doi: 10.1016/j.bmc.2013.12.048. Epub 2014 Jan 3.

17.

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.

Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D, Anderson KC.

Blood. 2014 Jan 30;123(5):706-16. doi: 10.1182/blood-2013-05-500033. Epub 2013 Dec 6.

18.

WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.

Liu H, Chen W, Liang C, Chen BW, Zhi X, Zhang S, Zheng X, Bai X, Liang T.

Cancer Lett. 2015 Jun 1;361(2):218-25. doi: 10.1016/j.canlet.2015.03.001. Epub 2015 Mar 5.

PMID:
25749422
19.

Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.

McBrayer SK, Yarrington M, Qian J, Feng G, Shanmugam M, Gandhi V, Krett NL, Rosen ST.

PLoS One. 2012;7(7):e41455. doi: 10.1371/journal.pone.0041455. Epub 2012 Jul 27.

20.

miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma.

Yang Y, Li F, Saha MN, Abdi J, Qiu L, Chang H.

Clin Cancer Res. 2015 May 15;21(10):2399-411. doi: 10.1158/1078-0432.CCR-14-1437. Epub 2015 Feb 27.

Supplemental Content

Support Center